<DOC>
	<DOCNO>NCT00052611</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . Celecoxib may effective prevent head neck cancer patient oral leukoplakia head neck dysplasia . PURPOSE : Phase II trial study effectiveness celecoxib prevent cancer patient oral leukoplakia and/or head neck dysplasia .</brief_summary>
	<brief_title>Celecoxib Preventing Cancer Patients With Oral Leukoplakia and/or Head Neck Dysplasia</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate , term prostaglandin E2 expression , patient oral leukoplakia and/or dysplasia treat celecoxib . - Determine change biomarkers include COX-2 , Ak+ , Ki-67 , BCL2 , BAX , VEGF , CD31 , patient treat drug . - Determine efficacy drug , term reduce size oral leukoplakia lesion presence dysplasia , patient . - Correlate change biomarker expression response oral leukoplakia lesion and/or dysplasia patient treat drug . - Determine toxic effect drug patient . OUTLINE : This open-label , multicenter study . Patients receive oral celecoxib twice daily 3 month . After 3 month , patient undergo repeat biopsy . Patients positive response receive celecoxib additional 9 month . Patients follow every 3-6 month 1 year . PROJECTED ACCRUAL : A total 20 patient accrue study within 30 month .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Oral leukoplakia clinical examination AND/OR More one prior squamous cell carcinoma ( SCC ) head neck dysplasia biopsy within past 6 month Carcinoma situ new leukoplakia eligible provide treatment prior carcinoma complete 9 month ago PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 12 month Hematopoietic Platelet count least 100,000/mm^3 Absolute neutrophil count great 1,500/mm^3 No bleed diathesis Hepatic Bilirubin less 1.5 time upper limit normal ( ULN ) Transaminases less 1.5 time ULN PT/PTT less 1.5 time ULN No acute chronic liver disease Renal Creatinine less 1.5 time ULN Urine protein le 2+ No acute chronic renal insufficiency Cardiovascular No New York Heart Association class II congestive heart failure No prior myocardial infarction No angina No known coronary artery disease Pulmonary No advance chronic obstructive pulmonary disease require home oxygen use Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No infection within past 2 week No concurrent infection No concurrent tobacco use ( e.g. , cigarette , cigar , pipe , chew tobacco ) At least 1 month since prior use No active alcohol abuse No history gastrointestinal ulcer No history anaphylactoid reaction aspirin , nonsteroidal antiinflammatory drug ( NSAIDs ) cyclooxygenase2 ( COX2 ) inhibitors No concurrent active malignancy except nonmelanoma skin cancer No contraindication nasopharyngoscopy biopsy PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent biologic therapy Chemotherapy No concurrent chemotherapy Endocrine therapy More 3 month since prior absorbed steroid , include inhale nasal steroid ( 3 time week least 2 consecutive week ) Prior mometasone allow Radiotherapy No concurrent radiotherapy Surgery Prior surgery SCC head neck allow provided patient cancer free least 9 month Other More 3 month since prior fulldose aspirin , COX2 inhibitor , NSAIDs ( least 3 time week least 2 week ) More 3 month since prior retinoids selenium No concurrent lithium fluconazole No concurrent diuretic congestive heart failure No concurrent angiotensinconverting enzyme inhibitor Concurrent aspirin allow dosage great 81 mg per day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2005</verification_date>
	<keyword>lip oral cavity cancer</keyword>
	<keyword>paranasal sinus nasal cavity cancer</keyword>
	<keyword>hypopharyngeal cancer</keyword>
	<keyword>laryngeal cancer</keyword>
	<keyword>oropharyngeal cancer</keyword>
	<keyword>nasopharyngeal cancer</keyword>
	<keyword>salivary gland cancer</keyword>
</DOC>